Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | JAK2 | O60674 | 4/20 | 0.52 |
| ▸ | JAK1 | P23458 | 4/20 | 0.52 |
| ▸ | TYK2 | P29597 | 4/20 | 0.52 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | FEN1 | P39748 | 1/20 | 0.47 |
| ▸ | ALDH2 | P05091 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.45 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.45 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7217875 | 0.88 | ALDH1A1 (0.50) | ALDH1A1HPGDPOLBJAK2JAK1 | |
| SCHEMBL8932345 | 0.88 | P2RX7 (0.57) | ALDH1A1HPGDPOLBJAK2JAK1 | |
| SCHEMBL5022118 | 0.88 | HPGD (0.59) | HPGDPOLBJAK2JAK1TYK2 | |
| SCHEMBL18885419 | 0.87 | TYK2 (0.57) | ALDH1A1HPGDPOLBJAK2JAK1 | |
| SCHEMBL7224446 | 0.85 | HPGD (0.46) | ALDH1A1HPGDPOLBJAK2JAK1 | |
| SCHEMBL7217139 | 0.85 | ALDH1A1 (0.46) | ALDH1A1HPGDPOLBJAK2JAK1 | |
| SCHEMBL10289215 | 0.85 | ALDH1A1 (0.57) | ALDH1A1HPGDPOLBJAK2JAK1 | |
| SCHEMBL7224440 | 0.84 | HPGD (0.45) | ALDH1A1HPGDPOLBJAK2JAK1 | |
| SCHEMBL15038350 | 0.83 | ALDH1A1 (0.65) | ALDH1A1HPGDPOLBJAK2JAK1 | |
| SCHEMBL19541876 | 0.83 | HPGD (0.56) | ALDH1A1HPGDPOLBJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377768-B2 | Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | LYCERA CORPORATION (US) | 2019-08-13 | — | — | US | disclosed |
| US-10208061-B2 | Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180179224-A1 | Tetrahydro[1,8]naphthyridine Sulfonamide And Related Compounds for Use as Agonists of RORy and the Treatment of Disease | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2018-06-28 | — | — | US | disclosed |
| US-20180099005-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | HOFFMANN-LA ROCHE, INC. | 2018-04-12 | — | — | US | disclosed |
| EP-2846804-B1 | TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20170313722-A1 | TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME LLC | 2017-11-02 | — | — | US | disclosed |
| US-20090131657-A1 | PROCESS FOR ALKENYLATING CARBOXAMIDES | BASF SE (DE) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099005-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | ITGB1, ITGA4, ITGB4 | ALDH1A1 2009/4885HPGD 4315/4885POLB 2097/4885 |
| US-10377768-B2 | Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | RORC, RORB, RORA | ALDH1A1 1640/4885HPGD 452/4885POLB 3571/4885 |
| US-20170313722-A1 | TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | RORC, RORB, RORA | ALDH1A1 1640/4885HPGD 452/4885POLB 3571/4885 |
| US-20180179224-A1 | Tetrahydro[1,8]naphthyridine Sulfonamide And Related Compounds for Use as Agonists of RORy and the Treatment of Disease | RORA, RORC, RORB | ALDH1A1 224/4885HPGD 561/4885POLB 2633/4885 |
| US-10208061-B2 | Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | RORC, RORA, RORB | ALDH1A1 322/4885HPGD 539/4885POLB 3306/4885 |
| US-20090131657-A1 | PROCESS FOR ALKENYLATING CARBOXAMIDES | PRMT5, CYC1, CBR3 | ALDH1A1 1506/4885HPGD 3495/4885POLB 938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.